(Reuters)—Mesoblast Ltd. on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial. Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with…
Articles by Natasha Yetman
Health Has Improved in States That Expanded Low-Income Insurance Options
(Reuters Health)—In states that expanded either their Medicaid programs or private insurance options for low-income Americans, beneficiaries used more outpatient and preventive care and less emergency care. They also had better subjective overall health, compared with low-income residents of states with no expanded coverage. All states participate in Medicaid, a partnership with the federal government…
E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis
(Reuters Health)—As more and more sick patients are going online and using social media to search for answers about their health, it’s raising a lot of thorny ethical questions for doctors. “The internet and ready access to vast amounts of information are now permanent aspects of how we live our lives, including how we think…
U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller
WASHINGTON (Reuters)—A U.S. advisory panel on Thursday recommended approval of Egalet Corp’s long-acting opioid painkiller, Arymo ER (morphine sulfate), saying it dulls pain and could deter abuse by addicts seeking a quick high. The panel recommended that the U.S. Food and Drug Administration (FDA) approve the drug and said it deters, but does not eliminate,…
Cephalon, U.S. States Reach $125 Million Settlement Over Generic Drugs
WASHINGTON (Reuters)—Cephalon has reached a $125 million settlement with 48 states in connection with its alleged efforts to delay generic versions of its blockbuster sleep disorder drug modafinil (Provigil) from entering the market, New York Attorney General Eric Schneiderman said on Thursday. The settlement with Cephalon, now owned by Teva Pharmaceuticals, comes a little more…
Banner Health Says Hackers May Have Gained Access to Patient Data
(Reuters)—Banner Health, a non-profit organization that runs a chain of hospitals, says hackers may have gained unauthorized access to patient, physician and beneficiary data. Phoenix-based Banner said it was notifying 3.7 million patients, health plan members, food and beverage customers, physicians and healthcare providers about the attack, which occurred between June 23 and July 7….
Generic TNF-Alpha Inhibitors Comparable to Established Brands
NEW YORK (Reuters Health)—Biosimilar tumor necrosis factor-alpha inhibitors appear equivalent to the branded original versions, according to a systematic review and meta-analysis. As Dr. G. Caleb Alexander tells Reuters Health by email, “biologic treatments represent a rapidly growing proportion of prescription drug expenditures and thus there is enormous interest in whether or not biosimilar products…
Non-Celiac Wheat Sensitivity Is an Immune Disorder, Too
(Reuters Health)—People who feel ill after eating wheat, but who don’t have celiac disease, may finally have a biological explanation for their symptoms, a new study suggests. Researchers from the U.S. and Italy found that people who claim to have wheat sensitivity do have biological reactions to gluten proteins in wheat, rye and barley. It’s…
Milestones of Rheumatology Education
In 2013, a collaboration began to advance the training and assessment of fellows. The result: A uniform set of educational reporting milestones for all internal medicine subspecialties was developed. Key stakeholders were then asked to develop a list of entrustable professional activities (EPAs), a set of responsibilities any specialist should be able to perform, for their subspecialties. The ACR’s Next Accreditation System working group developed 14 EPAs for rheumatology…
Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA
NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report. Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 97
- Next Page »